GEMZ Corporation (GMZP): I am no expert on ice shacks, but I beli...

surfkast · 2024-08-23T12:09:53.2200000Z

I am no expert on ice shacks, but I believe the shipping container idea would be much heavier than the ones commercially available from the specialty manufactures I believe that average 20 foot container weighs in at about 5000 pounds. I am guessing they would make up to three out of each 20 foot container. The finished product would then weigh in the 1700 pound range. Pretty bulky I believe.

Play Episode

6min

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Proactive - Interviews for investors

St George Mining unveils major JORC resource

St George Mining Ltd executive chairman John Prineas talked with Proactive about the company's newly announced maiden JORC resource, which he says could be among the world’s most significant niobium and rare earth deposits. Prineas said the deposit features over 500 intercepts of high-grade mineralisation and boasts a rare combination of high grades and shallow mineralisation starting at surface, supporting an open pit development. “We think, possibly the second highest niobium deposit in terms of grade and, probably one of the highest rare earth deposits,” he told Proactive. He confirmed the company has already seen interest from industry players, with some expressing interest in potential partnerships and even mergers. The resource was released following St George’s acquisition of the project in late February, and the company has committed to a drill program starting in the coming weeks. According to Prineas, this program could potentially double the existing resource. In Brazil, St George has assembled an experienced in-country team and engaged a global EPC contractor to progress mine development. The company has also begun metallurgical and downstream processing studies and believes the project will deliver a commercial-grade product, supported by decades of similar production by neighbours CBMM. 👉 For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. #StGeorgeMining #Niobium #RareEarths #JORCResource #MiningExploration #ASX #CriticalMinerals #BrazilMining #ResourceUpdate #MineralDiscovery #JohnPrineas #ProactiveInvestors

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Abacus Global Management CEO on 2024 highlights and 2025 targets

Abacus Global Management (NASDAQ:ABL) CEO Jay Jackson takes Proactive's Stephen Gunnion through the company’s strong financial performance in 2024 and its strategic outlook for 2025. The pioneering alternative asset manager reported 69% year-over-year revenue growth for 2024, with the fourth quarter alone seeing a 40% increase. Jackson noted that 2023 was already a record year, and 2024 surpassed that benchmark by over 50%. The company has issued guidance for 2025 that anticipates adjusted net income to rise by between 51% and 68%, driven by continued demand for non-correlated assets. Founded over 20 years ago, Abacus recently rebranded from Abacus Life to better reflect its identity as an alternative asset manager. Jackson explained, “We're an asset manager... and we also own a large institutional asset manager in Luxembourg,” underlining the firm’s expanding global footprint. Growth drivers include strategic acquisitions, expansion of its financial advisor channel, and development in its technology division. Jackson emphasized the role of AI in analyzing health and lifespan data to support financial planning, stating, “Think about the billion scenarios in someone's lifespan… AI helps us understand more accurate outcomes.” Jackson believes 2025 will bring increasing attention to the firm’s asset management operations, complementing its origination and technology capabilities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #AbacusGlobal #AlternativeAssets #JayJackson #AssetManagement #LifeInsuranceInvesting #AIinFinance #FinancialPlanning #SmallCapStocks #2025Outlook #InvestorInsights #NonCorrelatedAssets #TechInFinance

Followers	1049
Posts	118761
Boards Moderated	10
Alias Born	06/10/2006

Volume:	3,268,547
Day Range:	0.0001 - 0.0002
Bid:	0.0001
Ask:	0.0002
Last Trade Time:	12:02:37 PM EDT
Total Trades:	5

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

GMZP Detailed Quote

Recent GMZP News

More GMZP News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent GMZP News

Go Ad-Free